Bisphosphonates and hip and nontraumatic subtrochanteric femoral fractures in the veterans health administration

Journal of Clinical Rheumatology

Volumn 20, Issue 7, 2014, Pages 357-362

  Safford, Monika M ^a   Barasch, Andrei ^a   Curtis, Jeffrey R ^a   Outman, Ryan ^a   Saag, Kenneth ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Atypical fracture; Bisphosphonates; Safety

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; PARATHYROID HORMONE[1-34]; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; DEMOGRAPHY; DEPENDENT VARIABLE; ELECTRONIC MEDICAL RECORD; FEMALE; FEMUR FRACTURE; FEMUR SUBTROCHANTERIC FRACTURE; FOLLOW UP; FRAGILITY FRACTURE; HAZARD RATIO; HIGH RISK PATIENT; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OBSERVATIONAL STUDY; OSTEOPOROSIS; RETROSPECTIVE STUDY; SOCIAL ASPECT; VERY ELDERLY; VETERANS HEALTH; DRUG ADMINISTRATION; FRACTURES, SPONTANEOUS; HIP FRACTURES; INCIDENCE; MIDDLE AGED; OSTEOPOROTIC FRACTURES; RISK; VETERAN;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FRACTURES, SPONTANEOUS; HIP FRACTURES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; OSTEOPOROTIC FRACTURES; RETROSPECTIVE STUDIES; RISK; VETERANS;

EID: 84916210505     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0000000000000170     Document Type: Article

References (40)

1. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357: 1799-1809.
2. Bauer DC, Garnero P, Hochberg MC, et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: The fracture intervention trial. J Bone Miner Res. 2006;21: 292-299.
3. Black DM, Boonen S, Delmas P, et al. Reviewof comparative effectiveness of treatments to prevent fractures. Ann Intern Med. 2008;148: 885-886; author reply 887.
4. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356: 1809-1822.
5. Kilgore ML, Morrisey MA, Becker DJ, et al. Health care expenditures associated with skeletal fractures among Medicare beneficiaries, 1999-2005. J Bone Miner Res. 2009;24: 2050-2055.
6. Teng GG, Curtis JR, Saag KG. Mortality and osteoporotic fractures: Is the link causal, and is it modifiable? Clin Exp Rheumatol. 2008;26: S125-S137.
7. Colon-Emeric C, Lyles KW, Levine DA, et al. Prevalence and predictors of osteoporosis treatment in nursing home residents with known osteoporosis or recent fracture. Osteoporos Int. 2007;18: 553-559.
8. Farley JF, Blalock SJ. Trends and determinants of prescription medication use for treatment of osteoporosis. Am J Health Syst Pharm. 2009;66: 1191-1201.
9. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med. 2008;358: 1304-1306.
10. Neviaser AS, Lane JM, Lenart BA, et al. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008;22: 346-350.
11. Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: A caution. J Bone Joint Surg Br. 2007; 89: 349-353.
12. Armamento-Villareal R, Napoli N, Panwar V, et al. Suppressed bone turnover during alendronate therapy for high-Turnover osteoporosis.N Engl J Med. 2006;355: 2048-2050.
13. Cheung RK, Leung KK, Lee KC, et al. Sequential non-Traumatic femoral shaft fractures in a patient on long-Term alendronate. Hong Kong Med J. 2007;13: 485-489.
14. Armamento-Villareal R, Napoli N, Diemer K, et al. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: A case series. Calcif Tissue Int. 2009;85: 37-44.
15. Somford MP, Draijer FW, Thomassen BJ, et al. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-Term treatment with alendronate: Clues to the mechanism of increased bone fragility. J BoneMiner Res. 2009;24: 1736-1740.
16. Capeci CM, Tejwani NC. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-Term alendronate therapy. J Bone Joint Surg Am. 2009;91: 2556-2561.
17. Kwek EB, Goh SK, Koh JS, et al. An emerging pattern of subtrochanteric stress fractures: A long-Term complication of alendronate therapy? Injury. 2008;39: 224-231.
18. Ing-Lorenzini K, Desmeules J, Plachta O, et al. Low-energy femoral fractures associated with the long-Term use of bisphosphonates: A case series from a Swiss university hospital. Drug Saf. 2009;32: 775-785.
19. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90: 1294-1301.
20. Odvina CV, Levy S, Rao S, et al. Unusual mid-shaft fractures during long-Term bisphosphonate therapy. Clin Endocrinol (Oxf). 2010;72: 161-168.
21. Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin EndocrinolMetab. 2008;93: 2948-2952.
22. Lenart BA, Neviaser AS, Lyman S, et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: A case control study. Osteoporos Int. 2008;20: 1353-1362.
23. Lee P, Seibel MJ. More on atypical fractures of the femoral diaphysis. N Engl J Med. 2008;359: 317 author reply 317-318.
24. Lee P, van der Wall H, Seibel MJ. Looking beyond low bone mineral density: Multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy. J Endocrinol Invest. 2007;30: 590-597.
25. Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: A register-based national cohort study. J Bone Miner Res. 2009;24: 1095-1102.
26. Vestergaard P, Schwartz F, Rejnmark L, et al. Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene. Osteoporos Int. 2011;22: 993-1001.
27. Black DM, Kelly MP, Genant HK, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl JMed. 2011;362: 1761-1771.
28. Kim SY, Schneeweiss S, Katz JN, et al. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J Bone Miner Res. 2011;26: 993-1001.
29. Park-Wyllie LY, Mamdani MM, Juurlink DN, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA. 2011;305: 783-789.
30. Schilcher J, Michaelsson K, Aspenberg P. bisphosphonate use and atypical fractures of the femoral shaft. N Engl JMed. 2011;364: 1728-1737.
31. Giusti A, Hamdy NA, Dekkers OM, et al. Atypical fractures and bisphosphonate therapy: A cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone. 2011;48: 966-971.
32. Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies. Bone;47: 169-180.
33. Thompson RN, Phillips JR,McCauley SH, et al. Atypical femoral fractures and bisphosphonate treatment: Experience in two large United Kingdom teaching hospitals. J Bone Joint Surg Br;94: 385-390.
34. Wang Z, Bhattacharyya T. Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007. J BoneMiner Res;26: 553-560.
35. Warriner AH, Patkar NM, Curtis JR, et al. Which fractures are most attributable to osteoporosis? J Clin Epidemiol. 2011;64: 46-53.
36. Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care. 1998;36: 8-27.
37. Ray WA. Evaluating medication effects outside of clinical trials: New-user designs. Am J Epidemiol. 2003;158: 915-920.
38. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43: 1130-1139.
39. Shane E, Burr D, Ebeling PR, et al.Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res;25: 2267-2294.
40. Nieves JW, Bilezikian JP, Lane JM, et al. Fragility fractures of the hip and femur: Incidence and patient characteristics. Osteoporos Int;21: 399-408.